{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:26:58Z","timestamp":1793608018018,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005317","name":"Kermanshah University of Medical Sciences","doi-asserted-by":"publisher","award":["50007398"],"award-info":[{"award-number":["50007398"]}],"id":[{"id":"10.13039\/501100005317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129134","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:03:14Z","timestamp":1790060594000},"page":"129134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical development of human vaccine candidates against Shigella flexneri: a systematic review of clinical trials"],"prefix":"10.1016","volume":"92","author":[{"given":"Mosayeb","family":"Rostamian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Chegene Lorestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayebe","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pourya","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyghobad","family":"Ghadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129134_bb0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","article-title":"Shigellosis","volume":"391","author":"Kotloff","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129134_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032448","article-title":"Molecular mechanisms of Shigella pathogenesis; recent advances","volume":"24","author":"Pakbin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.129134_bb0015","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.BAI-0023-2019","article-title":"Shigella pathogenesis: new insights through advanced methodologies","volume":"7","author":"Schnupf","year":"2019","journal-title":"Microbiol Spectrum"},{"key":"10.1016\/j.vaccine.2026.129134_bb0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016717","article-title":"The inside story of Shigella invasion of intestinal epithelial cells","volume":"3","author":"Carayol","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2026.129134_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9020451","article-title":"The Shigella type III secretion system: an overview from top to bottom","volume":"9","author":"Muthuramalingam","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2026.129134_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijid.2023.01.034","article-title":"Consequences of Shigella infection in young children: a systematic review","volume":"129","author":"Libby","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129134_bb0035","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129134_bb0040","first-page":"11","article-title":"Incidence of Shigella intestinal infections, active component, U.S. Armed Forces, 2007\u20132016","volume":"24","author":"Williams","year":"2017","journal-title":"Msmr"},{"key":"10.1016\/j.vaccine.2026.129134_bb0045","first-page":"222","article-title":"The epidemiology of travel-associated shigellosis--regional risks, seasonality and serogroups","volume":"51","author":"Ekdahl","year":"2005","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2026.129134_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41579-024-01126-x","article-title":"Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions","volume":"23","author":"Scott","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0055","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(25)01033-5","article-title":"Shigellosis","volume":"406","author":"Hendrick","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129134_bb0060","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1186\/s12879-024-09945-2","article-title":"Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis","volume":"24","author":"Nyarkoh","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129134_bb0065","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1016\/j.vaccine.2023.06.052","article-title":"Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry","volume":"41","author":"Kelly","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129134_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-023-00906-1","article-title":"Antimicrobial-resistant Shigella: where do we go next?","volume":"21","author":"Baker","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0075","doi-asserted-by":"crossref","first-page":"e1819","DOI":"10.1016\/S2214-109X(23)00421-7","article-title":"Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries","volume":"11","author":"Giersing","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.129134_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100368","article-title":"Exploring Shigella vaccine priorities and preferences: results from a mixed-methods study in low- and middle-income settings","volume":"15","author":"Fleming","year":"2023","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.129134_bb0085","article-title":"Shigella vaccines: the continuing unmet challenge","volume":"25","author":"Lu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.129134_bb0090","article-title":"The Shigella vaccines pipeline","volume":"10","author":"MacLennan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129134_bb0095","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2026.2686291","article-title":"Accelerating Shigella vaccines: from decades of research to global access","volume":"25","author":"Tilahun","year":"2026","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2603736","article-title":"Shigella sonnei and Shigella flexneri: epidemiology supporting development of cross-protective vaccines","volume":"22","author":"Caradonna","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129134_bb0105","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.129134_bb0110","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.129134_bb0115","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/21645515.2019.1606972","article-title":"Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human","volume":"15","author":"Barel","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129134_bb0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2026.129134_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/jiag220","article-title":"First-in-human evaluation of the safety, genetic stability, and immunogenicity of an attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, vaccine strain CVD 1208S-122","volume":"234","author":"Chen","year":"2026","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129134_bb0130","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/424680","article-title":"Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208","volume":"190","author":"Kotloff","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129134_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00368-25","article-title":"Recent progress in enterotoxigenic Escherichia coli vaccine research and development","volume":"93","author":"Zhang","year":"2025","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.129134_bb0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2217\/fmb-2017-0128","article-title":"Causes of impaired oral vaccine efficacy in developing countries","volume":"13","author":"Parker","year":"2018","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054649","article-title":"Toward a Shigella vaccine: opportunities and challenges to fight an antimicrobial-resistant pathogen","volume":"24","author":"Raso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.129134_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.07.005","article-title":"Environmental enteric dysfunction induces regulatory T cells that inhibit local CD4+ T cell responses and impair oral vaccine efficacy","volume":"54","author":"Bhattacharjee","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.129134_bb0155","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/IAI.72.2.923-930.2004","article-title":"Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers","volume":"72","author":"Katz","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.129134_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10040489","article-title":"Pivotal Shigella vaccine efficacy trials-study design considerations from a Shigella vaccine trial design working group","volume":"10","author":"Pavlinac","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0165","article-title":"Toward a multivalent synthetic oligosaccharide-based conjugate vaccine against Shigella: state-of-the-art for a monovalent prototype and challenges","volume":"10","author":"Phalipon","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129134_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-023-00624-y","article-title":"A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults","volume":"8","author":"Meron-Sudai","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41541-026-01444-6","article-title":"A 25-year landscape of Escherichia coli vaccine development: systematic review of human clinical studies","volume":"11","author":"Rostamian","year":"2026","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0180","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/14760584.2019.1657012","article-title":"Glycoconjugate vaccines: current approaches towards faster vaccine design","volume":"18","author":"Micoli","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00019-23","article-title":"A novel Shigella O-polysaccharide-IpaB conjugate vaccine elicits robust antibody responses and confers protection against multiple Shigella serotypes","volume":"8","author":"Desalegn","year":"2023","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2026.129134_bb0190","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.apsb.2023.01.006","article-title":"Advanced subunit vaccine delivery technologies: from vaccine cascade obstacles to design strategies","volume":"13","author":"Hou","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.vaccine.2026.129134_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10040548","article-title":"From concept to clinical product: a brief history of the novel Shigella Invaplex vaccine\u2019s refinement and evolution","volume":"10","author":"Turbyfill","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10111353","article-title":"Recent progress in Shigella and Burkholderia pseudomallei vaccines","volume":"10","author":"Chapartegui-Gonz\u00e1lez","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.129134_bb0205","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1093\/infdis\/jiae273","article-title":"Safety and immunogenicity of a 4-component generalized modules for membrane antigens Shigella vaccine in healthy European adults: randomized, phase 1\/2 study","volume":"230","author":"Leroux-Roels","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129134_bb0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41541-023-00725-8","article-title":"A next-generation GMMA-based vaccine candidate to fight shigellosis","volume":"8","author":"Rossi","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/CVI.00608-15","article-title":"Evaluation of the safety, tolerability, and immunogenicity of an oral, inactivated whole-cell Shigella flexneri 2a vaccine in healthy adult subjects","volume":"23","author":"Chakraborty","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0220","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00683-13","article-title":"Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine","volume":"21","author":"Kaminski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111171","article-title":"Design and fabrication of a vaccine candidate based on rOmpA from Klebsiella pneumoniae encapsulated in silk fibroin-sodium alginate nanoparticles against pneumonia infection","volume":"125","author":"Shahbazi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123961","article-title":"Polydopamine-based nano adjuvant as a promising vaccine carrier induces significant immune responses against Acinetobacter baumannii-associated pneumonia","volume":"654","author":"Sabzi","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2026.129134_bb0235","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.molimm.2017.09.010","article-title":"Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7\/8 in a vaccine against leishmaniasis in BALB\/c mice","volume":"91","author":"Rostamian","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204491","article-title":"Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB\/c mice","volume":"13","author":"Rostamian","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.129134_bb0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0250","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/21645515.2019.1606971","article-title":"Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis","volume":"15","author":"Cohen","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.129134_bb0255","doi-asserted-by":"crossref","first-page":"1171213","DOI":"10.3389\/fcimb.2023.1171213","article-title":"Functional assays to evaluate antibody-mediated responses against Shigella: a review","volume":"13","author":"Boero","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0260","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129134_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020212","article-title":"The ongoing journey of a Shigella bioconjugate vaccine","volume":"10","author":"Martin","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129134_bb0270","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129134_bb0275","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/IAI.69.7.4545-4553.2001","article-title":"Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults","volume":"69","author":"Fries","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.129134_bb0280","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.vaccine.2018.12.067","article-title":"Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection","volume":"37","author":"Ledov","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129134_bb0285","series-title":"A candidate Ac(3)-S-LPS vaccine against S. flexneri 1b, 2a, 3a, 6, and Y activates long-lived systemic and mucosal immune responses in healthy volunteers: results of an open-label, randomized phase 2 clinical trial","author":"Ledov","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129134_bb0290","article-title":"Safety and immunogenicity of a Shigella bivalent conjugate vaccine (ZF0901) in 3-month- to 5-year-old children in China","volume":"10","author":"Mo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129134_bb0295","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/IAI.69.3.1351-1357.2001","article-title":"Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel","volume":"69","author":"Passwell","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.129134_bb0300","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.129134_bb0305","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129134_bb0310","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2011.07.033","article-title":"Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine","volume":"29","author":"Riddle","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129134_bb0315","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0320","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.vaccine.2008.10.081","article-title":"Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates","volume":"27","author":"Simon","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129134_bb0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2011.02.003","article-title":"Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates","volume":"139","author":"Simon","year":"2011","journal-title":"Clinical Immunology (Orlando, Fla)"},{"key":"10.1016\/j.vaccine.2026.129134_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00374","article-title":"Gut-homing conventional plasmablasts and CD27(\u2212) plasmablasts elicited after a short time of exposure to an oral live-attenuated Shigella vaccine candidate in humans","volume":"5","author":"Toapanta","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0335","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-018-1439-1","article-title":"T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans","volume":"16","author":"Toapanta","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.vaccine.2026.129134_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291664","article-title":"Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate","volume":"14","author":"Toapanta","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129134_bb0345","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1016\/j.vaccine.2010.06.086","article-title":"Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers","volume":"28","author":"Tribble","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:37:30Z","timestamp":1793605050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":69,"alternative-id":["S0264410X26009436"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129134","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical development of human vaccine candidates against Shigella flexneri: a systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129134"}}